Methods for the treatment of retroviral infections
US5141923A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 31, 1990 |
| Grant date | Aug 25, 1992 |
| Priority date | — |
| Expiry date | Dec 31, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/168
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel methods for the treatment of retroviral infection, particularly HIV disease. According to the present invention, human HIV infected hosts were selected who had been on a stable dose of an anti-retroviral agent, such as zidovudine, for up to two years prior to administration of the ribosomal inhibiting protein trichosanthin, and who had failed anti-retroviral therapy, as manifest by decrease in CD4+ cells on at least two serial measurements, or loss of over 50 CD4+ cells/mm.sup.3 /year. These patients remained on the same dose of anti-retroviral agent (AZT or ddI) and received trichosanthin, 1.2 mg weekly, then monthly. A significant number of patients demonstrated improved CD4+ cell counts following administration of trichosanthin as compared to CD4+ cell counts prior to adminstration of the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.